1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Actinium Pharmaceuticals submitted a compliance plan to NYSE American on June 18, 2026, describing actions management intends to take to restore compliance with listing standards. The exchange had notified the company on May 27, 2026 that its stockholders' equity was below the $4.0 million minimum required under Section 1003(a)(ii) of the NYSE American Company Guide, which applies after losses in three of four recent fiscal years.
June 18, 2026: Company submitted its compliance plan to NYSE American.
May 27, 2026: Company received the NYSE American notice regarding stockholders' equity.
Required minimum: stockholders' equity of $4.0 million or more under Section 1003(a)(ii).
The filing does not specify the individual actions management plans to take.
GRI Bio said on June 18, 2026 that the U.S. Food and Drug Administration granted Orphan Drug Designation to GRI-0621, its oral investigational therapy for idiopathic pulmonary fibrosis (IPF). The designation provides potential benefits such as seven years of U.S. market exclusivity upon approval, but the filing does not report revenue, earnings, or changes to guidance.
FDA granted Orphan Drug Designation to GRI-0621 for IPF, announced June 18, 2026
Orphan designation applies to diseases affecting fewer than 200,000 people in the U.S.; benefits include potential seven years of U.S. market exclusivity upon approval
GRI-0621 was evaluated in a 35-patient Phase 2a trial (GRI-0621-IPF-02), which the company says met its primary, secondary and exploratory endpoints
Otter Tail's subsidiaries Northern Pipe Products and Vinyltech agreed on June 17, 2026 to pay $30 million into a settlement fund to resolve end-user class claims in the PVC Pipe Antitrust Litigation. The settlement requires court approval, and the company says it will use available cash and does not expect a material adverse effect on its financial position or liquidity.
Settlement amount: $30 million, paid into a fund after preliminary court approval, with payment due about 21 days after that approval.
Settlement covers End-User Class claims in In re: PVC Pipe Antitrust Litigation (Case No. 1:24-cv-07639), U.S. District Court for the Northern District of Illinois.
The company does not admit wrongdoing and says it will keep defending itself if the settlement is not finalized.
The filing says the settlement is not expected to have a material adverse effect on financial position or liquidity.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.